Cellectis (Paris: ALCLS) (Alternext: ALCLS) (NASDAQ: CLLS)a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France.
CLLS lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM.
CLLS has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia.
Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
March 4, 2021
RegMed Investors’ (RMi) pre-open: slim pickings
February 24, 2021
RegMed Investors’ (RMi) closing bell: volatility provides a comeback
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cellectis (CLLS) – Opened 2018 at $29.90, saw a high of $33.33; February opened at $31.01, slipping to $28.87 and regaining its altitude at $32,65 on 2/16. One key factor for 2018, The US has granted (2/13/18) Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday. The patents come on the back of another granted last year by the European Patent Office. CLBS intended to make the three patents available for future licensing deals. The gene therapy sector has generated fierce patent disputes in recent months, as well as merger and acquisition activity.buy
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors